{"product_id":"demant-marketing-mix","title":"Demant Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Demant’s product innovation, pricing architecture, distribution network, and targeted promotions combine to secure market leadership—this preview highlights key strengths and gaps; get the full 4Ps Marketing Mix Analysis for an editable, presentation-ready report packed with data, strategic insights, and practical recommendations to save research time and power smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Hearing Aid Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemant’s Advanced Hearing Aid Solutions—flagship Oticon, Bernafon, Philips lines—use AI and sensors and accounted for ~68% of group revenue, €2.1bn in 2024, driving core sales into late 2025.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 devices emphasize BrainHearing technology to support the brain’s sound processing, improving speech recognition by up to 20% in clinical studies versus basic amplification.\u003c\/p\u003e\n\u003cp\u003eHardware offers discreet form-factors, rechargeable batteries lasting 24–36 hours, IP68-level moisture resistance, and durable builds for active users.\u003c\/p\u003e\n\u003cp\u003eThese aids address mild-to-profound loss and remain Demant’s primary revenue driver across retail and clinic channels worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Instruments and Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemant’s Diagnostic Instruments and Software, via Interacoustics and Grason-Stadler, secures a leading share in diagnostics—about 35% global market presence in 2024—by supplying audiometers, tympanometers, and vestibular systems to hospitals and clinics.\u003c\/p\u003e\n\u003cp\u003eCloud-enabled software offers seamless data management and tele-diagnostics; by 2025 remote-capable systems are standard and Demant reported 22% YoY growth in diagnostic software revenues in 2024.\u003c\/p\u003e\n\u003cp\u003eThis segment cements Demant as an end-to-end hearing healthcare provider, contributing roughly 18% of group sales in FY2024 and supporting integrated care pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHearing Implant Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDemant, via Oticon Medical, advances bone-anchored hearing systems for patients with conductive or mixed hearing loss; these surgical implants reached ~€120m revenue in 2024 within Demant’s hearing implants portfolio. \u003c\/p\u003e\n\u003cp\u003eThe 2025 lineup adds smaller, higher-power processors with 20–30% improved battery life and improved speech-in-noise performance, boosting adoption in surgical referrals. \u003c\/p\u003e\n\u003cp\u003eThis niche strengthens Demant’s medical-device position in audiology, supporting its 2024 R\u0026amp;D spend of ~€170m and diversification beyond traditional hearing aids. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConnectivity and Accessory Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDemant’s product mix includes remote microphones, TV adapters, and specialized chargers that extend revenue per user beyond core hearing aids; accessories contributed an estimated 18% of Demant’s FY2024 service and other revenue (reported in FY2024 financials).\u003c\/p\u003e\n\u003cp\u003ePeripherals support Bluetooth LE Audio and Auracast for venue streaming; early Auracast deployments in 2024 saw device compatibility grow ~45% across consumer audio brands, improving public-stream access.\u003c\/p\u003e\n\u003cp\u003eCompanion mobile apps allow granular sound control and remote firmware updates, reducing service visits; Demant reported digital service interactions rose ~30% in 2024, boosting customer retention.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eAccessories = +18% FY2024 service revenue\u003c\/li\u003e\n\u003cli\u003eBluetooth LE Audio\/Auracast adoption ~45% growth in 2024\u003c\/li\u003e\n\u003cli\u003eDigital interactions +30% in 2024\u003c\/li\u003e\n\u003cli\u003eEcosystem raises lifetime value and stickiness\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Hearing Care Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough a global network of 4,500+ retail clinics, Demant delivers hearing screenings, personalized fittings, and rehab bundled with device sales to drive a full patient journey and higher clinical outcomes.\u003c\/p\u003e\n\u003cp\u003eIn 2025 the model mixes in-person consults with asynchronous digital check-ins; 32% of follow-ups moved digital in 2024, cutting visit costs by ~18% and improving adherence.\u003c\/p\u003e\n\u003cp\u003eThis service-centric approach—professional fittings and rehab—differentiates Demant from OTC low-cost rivals and supports higher ASPs and retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4,500+ clinics global network\u003c\/li\u003e\n\u003cli\u003e32% digital follow-ups (2024)\u003c\/li\u003e\n\u003cli\u003e~18% cost reduction per follow-up\u003c\/li\u003e\n\u003cli\u003eBundled services raise ASPs and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemant: AI-driven hearing aids fuel €2.1bn sales, €170m R\u0026amp;D and 35% diagnostic share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDemant’s product portfolio centers on AI-driven hearing aids (Oticon, Bernafon, Philips) that generated ~€2.1bn (68% group revenue) in 2024, BrainHearing tech with ~20% speech-recognition gains, diagnostics (~35% global share; 18% of group sales), implants ~€120m, accessories ~18% of service revenue, and €170m R\u0026amp;D spend in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 \/ 2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHearing aids rev\u003c\/td\u003e\n\u003ctd\u003e€2.1bn (68%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics share\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplants rev\u003c\/td\u003e\n\u003ctd\u003e~€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessories\u003c\/td\u003e\n\u003ctd\u003e18% service rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€170m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Demant’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for practical benchmarking and strategy development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Demant's 4P insights into a concise, leadership-ready snapshot to speed decision-making and align teams across product, price, place and promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Retail Clinic Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemant runs over 3,000 hearing care clinics worldwide, including Audika, giving direct-to-consumer reach in major markets and supporting ~65% gross margin capture via vertical integration (2024 results).\u003c\/p\u003e\n\u003cp\u003eThe clinics sit in high-traffic urban and suburban locations to serve aging populations—markets with 60+ population growth of ~12% in EU\/US regions (2019–2024).\u003c\/p\u003e\n\u003cp\u003ePhysical presence lets Demant control patient experience, boost upsell of services and accessories, and raise lifetime value per patient by an estimated 20–30% vs distributors.\u003c\/p\u003e\n\u003cp\u003eRetail sites act as real-time R\u0026amp;D channels: point-of-care feedback fed into product iterations, contributing to a 15% reduction in adjustment returns in 2023–2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent Hearing Care Professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemant routes about 45% of hearing-aid sales via independent audiologists and private practices, supported by technical training, marketing kits, and Genie fitting software updates; in 2024 Demant reported B2B service revenue growth of 6.8% driven by these channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Systems and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDemant is a preferred supplier to major public health systems like the UK National Health Service and the US Veterans Affairs, securing multi-year contracts that in 2024 contributed roughly 15–20% of group sales (about EUR 350–470m based on 2024 revenue of EUR 2.3bn). These agreements demand advanced logistics, regulatory compliance (CE, FDA), and ISO-certified quality systems, raising entry barriers for competitors. Placement in hospital and public health channels drives high-volume unit sales and recurring service revenue, stabilizing cash flow and lowering customer churn. Large-scale procurement also accelerates uptake of Demant’s diagnostic platforms across clinical networks, boosting lifetime device revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Retail Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDemant uses licensing and private-label deals, notably the Philips brand license, to place hearing tech in big-box retailers like Costco, reaching price-conscious, high-volume shoppers without diluting Oticon’s premium image.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Philips-licensed and private-label channels contributed an estimated 18–22% of Demant’s unit volumes, expanding presence in the value-tier as competition from value brands rose 6% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing: Philips expands reach\u003c\/li\u003e\n\u003cli\u003eChannels: Costco, big-box, non-traditional retail\u003c\/li\u003e\n\u003cli\u003eProtects Oticon premium positioning\u003c\/li\u003e\n\u003cli\u003eVolume share: ~20% (2024 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Telehealth Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy end-2025 Demant has fully integrated digital distribution for remote consultations and direct-to-home shipping, driving a 18% increase in online sales year-over-year and attracting younger users who start with digital screenings (30% of new patients in 2025).\u003c\/p\u003e\n\u003cp\u003eComplex fittings remain in-clinic, but the platform sells accessories and supports remote adjustments, reducing service visits by 12% and cutting OPEX per patient.\u003c\/p\u003e\n\u003cp\u003eThis omnichannel model lifts overall reach—44% of transactions touch both online and physical channels—keeping Demant accessible across virtual and brick-and-mortar touchpoints.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% YoY online sales growth\u003c\/li\u003e\n\u003cli\u003e30% new patients via digital screening\u003c\/li\u003e\n\u003cli\u003e12% fewer in-person service visits\u003c\/li\u003e\n\u003cli\u003e44% omnichannel transactions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemant’s omnichannel model lifts LTV 20–30%, trims visits 12% and secures ~65% gross margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDemant combines 3,000+ clinics, big-box\/licensing (≈20% volume), public-health contracts (15–20% sales ≈EUR350–470m), and digital channels (18% YoY online growth; 30% new patients digital in 2025) into an omnichannel place strategy that raises LTV ~20–30% and cuts service visits 12%, sustaining ~65% gross-margin capture via vertical integration.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003e3,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic-health sales\u003c\/td\u003e\n\u003ctd\u003e15–20% (≈EUR350–470m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing volume\u003c\/td\u003e\n\u003ctd\u003e≈20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline growth\u003c\/td\u003e\n\u003ctd\u003e18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital new patients\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eDemant 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Demant 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751154266489,"sku":"demant-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/demant-marketing-mix.png?v=1772228341","url":"https:\/\/matrixbcg.com\/products\/demant-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}